Ensysce submits UK MHRA Phase 2a trial protocol for CRPS drug candidate CY200
ENSC•Ensysce submitted a Phase 2a protocol for CY200 in complex regional pain syndrome type 1 to the UK MHRA for regulatory review. The planned UK study will be randomized, double-blind and placebo-controlled, assessing efficacy, safety and tolerability.
1. Protocol submitted
Ensysce submitted the Phase 2a protocol for its CY200 drug candidate in complex regional pain syndrome type 1 to the UK MHRA for regulatory review. The planned UK study will be randomized, double-blind and placebo-controlled, and will assess efficacy, safety and tolerability.
